Biotech company ISA Pharmaceuticals B.V. reported on Tuesday the receipt of US Food and Drug Administration (FDA) Fast Track Designation (FTD) to facilitate the development of its lead product ISA101b for the treatment of oropharyngeal cancer (OPC).
The company received the US FDA's FTD for ISA101b to improve the survival and delay progression of recurrent and metastatic Human Papilloma Virus (HPV) 16 positive oropharyngeal cancer (OPC). Head-and-neck cancer is a severe and life-threatening disease.
Using the company's proprietary Synthetic Long Peptide (SLP) technology, ISA101b induces strong and specific immune responses to HPV16 virus proteins and (re-)establishes a powerful T-cell immune response against virus infected and/or cancerous cells and tissues.
According to the company, ISA101b is studied in HPV16 positive cancers in combination with Libtayo (cemiplimab) in three phase two clinical trials under a strategic collaboration with Regeneron. Libtayo is an anti-PD-1 antibody that is being jointly developed by Regeneron and Sanofi.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT